Metabolic syndrome associated with toenail onychomycosis in Taiwanese with diabetes mellitus

Background  Onychomycosis is a complication of diabetes mellitus (DM), which has a deleterious impact on the quality of life.

[1]  E. Warshaw,et al.  Cost-effectiveness of diagnostic tests for toenail onychomycosis: a repeated-measure, single-blinded, cross-sectional evaluation of 7 diagnostic tests. , 2006, Journal of the American Academy of Dermatology.

[2]  S. Grundy,et al.  Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. , 2006, Journal of the American College of Cardiology.

[3]  J. Ekoé,et al.  Diagnosis and Classification of Diabetes Mellitus , 2019, Encyclopedia of Endocrine Diseases.

[4]  M. Chou,et al.  The causative pathogens of onychomycosis in southern Taiwan , 2005, Mycoses.

[5]  G. Piérard,et al.  The nail under fungal siege in patients with type II diabetes mellitus , 2005, Mycoses.

[6]  F. Kianifard,et al.  A comparison of KOH and culture results from two mycology laboratories for the diagnosis of onychomycosis during a randomized, multicenter clinical trial: a subset study. , 2005, Journal of the American Podiatric Medical Association (Print).

[7]  S. Tam,et al.  Determinants of postprandial triglyceride and remnant‐like lipoproteins in type 2 diabetes , 2005, Diabetes/metabolism research and reviews.

[8]  S. Walrand,et al.  In vivo evidences that insulin regulates human polymorphonuclear neutrophil functions , 2004, Journal of leukocyte biology.

[9]  J. Sowers.  Diabetes in the elderly and in women: cardiovascular risks. , 2004, Cardiology clinics.

[10]  S. Haffner,et al.  Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome , 1991, Diabetologia.

[11]  J. Meigs,et al.  Should the Insulin Resistance Syndrome be Treated in the Elderly? , 2004, Drugs & aging.

[12]  F. Renström,et al.  In vitro reversal of hyperglycemia normalizes insulin action in fat cells from type 2 diabetes patients: is cellular insulin resistance caused by glucotoxicity in vivo? , 2003, Metabolism: clinical and experimental.

[13]  S. Dogra,et al.  Epidemiology of onychomycosis in patients with diabetes mellitus in India , 2002, International journal of dermatology.

[14]  P. Chou,et al.  Epidemiology of type 2 diabetes in Taiwan. , 2001, Diabetes research and clinical practice.

[15]  C. Gianni,et al.  Usefulness of Histological Examination for the Diagnosis of Onychomycosis , 2001, Dermatology.

[16]  Kow-Tong Chen,et al.  Prevalence of type 2 diabetes mellitus in Taiwan: ethnic variation and risk factors. , 2001, Diabetes research and clinical practice.

[17]  S. Bagnasco.  How Renal Cells Handle Urea , 2001, Cellular Physiology and Biochemistry.

[18]  P. Rich.  Onychomycosis and tinea pedis in patients with diabetes. , 2000, Journal of the American Academy of Dermatology.

[19]  A. R. Noriega,et al.  Prevalence and Risk Factors of Tinea Unguium and Tinea Pedis in the General Population in Spain , 2000, Journal of Clinical Microbiology.

[20]  Aditya K. Gupta,et al.  The prevalence and management of onychomycosis in diabetic patients. , 2000, European journal of dermatology : EJD.

[21]  D. Patrick,et al.  The impact of onychomycosis on quality of life: development of an international onychomycosis-specific questionnaire to measure patient quality of life. , 1999, Journal of the American Academy of Dermatology.

[22]  A. Gupta,et al.  Onychomycosis in diabetes. Management considerations. , 1999, Postgraduate medicine.

[23]  M. P. Kane,et al.  Management of toenail onychomycosis. , 1999, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[24]  D. Rigopoulos,et al.  Epidemiology of onychomycosis in southern Greece , 1998, International journal of dermatology.

[25]  R. Summerbell,et al.  Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicentre survey , 1998, The British journal of dermatology.

[26]  R. Kirsner,et al.  Routine histologic examination for the diagnosis of onychomycosis: an evaluation of sensitivity and specificity. , 1998, Cutis.

[27]  L. Levy,et al.  Epidemiology of onychomycosis in special-risk populations. , 1997, Journal of the American Podiatric Medical Association.

[28]  R. Aly,et al.  Double-blind, randomized comparison of itraconazole capsules vs. placebo in the treatment of toenail onychomycosis. , 1997, Cutis.

[29]  R. Scher,et al.  Newer systemic antifungal drugs for the treatment of onychomycosis. , 1996, Clinics in podiatric medicine and surgery.

[30]  B. Elewski.  Diagnostic techniques for confirming onychomycosis. , 1996, Journal of the American Academy of Dermatology.

[31]  G. Gibbons,et al.  Foot infections in diabetes: evaluation and management. , 1994, Current clinical topics in infectious diseases.

[32]  J. Sánchez,et al.  Prevalence of dermatophytosis in patients with diabetes. , 1992, Journal of the American Academy of Dermatology.

[33]  A. Mooradian,et al.  The Prevalence and Nature of Podiatric Problems in Elderly Diabetic Patients , 1991, Journal of the American Geriatrics Society.

[34]  D. Bild,et al.  Lower-Extremity Amputation in People With Diabetes: Epidemiology and Prevention , 1989, Diabetes Care.

[35]  R. M. Wilson,et al.  Neutrophil phagocytosis and killing in insulin-dependent diabetes. , 1986, Clinical and experimental immunology.

[36]  S A M JOHNSON,et al.  The cutaneous manifestations of diabetes mellitus. , 1948, The Nebraska state medical journal.